Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy

作者：Donnard Elisa; Asprino Paula F; Correa Bruna R; Bettoni Fabiana; Koyama Fernanda C; Navarro Fabio C P; Perez Rodrigo O; Mariadason John; Sieber Oliver M; Strau**erg Robert L; Simpson Andrew J G; Jardim Denis L F; Reis Luiz Fernando L; Parmigiani Raphael B; Galante Pedro A F; Camargo Anamaria A^*

来源：Oncotarget, 2014, 5(19): 9199-9213.

• colorectal cancer
• targeted therapy
• cell surface proteins
• somatic mutations

We carried out a mutational analysis of 3,594 genes coding for cell surface proteins (Surfaceome) in 23 colorectal cancer cell lines, searching for new altered pathways, druggable mutations and mutated epitopes for targeted therapy in colorectal cancer. A total of 3,944 somatic non-synonymous substitutions and 595 InDels, occurring in 2,061 (57%) Surfaceome genes were catalogued. We identified 48 genes not previously described as mutated in colorectal tumors in the TCGA database, including genes that are mutated and expressed in >10% of the cell lines (SEMA4C, FGFRL1, PKD1, FAM38A, WDR81, TMEM136, SLC36A1, SLC26A6, IGFLR1). Analysis of these genes uncovered important roles for FGF and SEMA4 signaling in colorectal cancer with possible therapeutic implications. We also found that cell lines express on average 11 druggable mutations, including frequent mutations (>20%) in the receptor tyrosine kinases AXL and EPHA2, which have not been previously considered as potential targets for colorectal cancer. Finally, we identified 82 cell surface mutated epitopes, however expression of only 30% of these epitopes was detected in our cell lines. Notwithstanding, 92% of these epitopes were expressed in cell lines with the mutator phenotype, opening new venues for the use of "general" immune checkpoint drugs in this subset of patients.

• 出版日期2014-10-15
• 单位河北医科大学